Bonner Carolyn F. 4

What Happened

• Carolyn F. Bonner, President and Chief Financial Officer of Medicus Pharma Ltd. (MDCX), was granted 100,000 derivative shares (reported as an "A" — award/grant) on March 30, 2026. The Form 4 lists an acquisition price of $0.00 and a reported transaction value of $0, indicating this was an equity award/compensation grant rather than a cash purchase. The filing was submitted on April 1, 2026.

Key Details

• Transaction date: 2026-03-30; Form 4 filed: 2026-04-01.
• Transaction type/code: Award/Grant (code A); derivative securities reported.
• Shares granted: 100,000; reported price: $0.00; reported value: $0.
• Shares owned after transaction: Not specified in the provided filing.
• Notable footnotes: None disclosed in the provided summary (no 10b5-1 plan, tax-withholding, or cashless sale noted).
• Timeliness: Filing date is April 1 for a March 30 transaction; no late-filing indication provided in the summary.

Context

• The $0 acquisition price and derivative classification typically mean this was an equity compensation grant (e.g., RSUs or a performance award) that may vest over time; it does not represent an open-market purchase. Such grants are common for executive compensation and do not, by themselves, indicate insider buying or selling intent. Watch future Form 4s for vesting, conversion to common shares, or subsequent sales that could affect ownership or market impact.